Judd Ali, Parry John, Hickman Matthew, McDonald Tamara, Jordan Laura, Lewis Kim, Contreras Marcela, Dusheiko Geoff, Foster Graham, Gill Noël, Kemp Katie, Main Janice, Murray-Lyon Iain, Nelson Mark
Centre for Research on Drugs and Health Behaviour, Department of Social Science and Medicine, Faculty of Medicine, Imperial College London, United Kingdom.
J Med Virol. 2003 Sep;71(1):49-55. doi: 10.1002/jmv.10463.
Oral fluid testing is an effective alternative to serum antibody testing for surveillance of human immunodeficiency virus (HIV) and hepatitis B infections, and is being extended to hepatitis C infections. The objective of this study was to determine and compare the sensitivity and specificity of a modified commercial assay for the detection of antibody to hepatitis C virus (anti-HCV) in oral fluids collected by two different oral fluid collection devices (the Epitope OraSure trade mark and Sarstedt Salivette ) and in dried fingerprick blood spots. In this study, 253 anti-HCV seropositive patients and 394 blood donors (all anti-HCV negative) were recruited between August 2000 and January 2001. Each participant provided oral fluid specimens by OraSure and Salivette, and at least one dried blood spot. Serum specimens were collected from the patients whenever possible. For those injecting drug users who did not provide a serum specimen, HCV status was established on the basis of previous testing. All the nonserum samples were tested for the presence of anti-HCV, using a modified Ortho HCV 3.0 SAVe enzyme-linked immunosorbent assay (ELISA) protocol. The recommended preliminary cutoffs for the modified ELISA were suboptimal. Further, the sensitivity, specificity, and positive and negative predictive values could be improved by varying the cutoff and taking into account the likely prevalence of HCV in the population under investigation. For instance, given a population with a 50% prevalence of anti-HCV, the optimal sensitivities of the modified assay on OraSure, Salivette, and dried blood spots were 92%, 83%, and virtually 100%, respectively, in contrast to 83%, 59%, and 99% using the preliminary cutoffs. The respective optimal specificities were 99%, 93%, and 100%. In conclusion, oral fluids collected by the OraSure device provide an extremely useful method to conduct public health surveillance of not only HIV, but also hepatitis C, among injecting drug users. In addition, dried blood spot specimens may be useful for surveillance and could be employed as a first line diagnostic specimen.
口腔液检测是用于监测人类免疫缺陷病毒(HIV)和乙型肝炎感染的血清抗体检测的一种有效替代方法,并且正在扩展到丙型肝炎感染的监测。本研究的目的是确定并比较一种改良的商业检测方法在通过两种不同的口腔液采集装置(Epitope OraSure商标和Sarstedt Salivette)采集的口腔液以及干血斑中检测丙型肝炎病毒抗体(抗-HCV)的敏感性和特异性。在本研究中,于2000年8月至2001年1月期间招募了253例抗-HCV血清阳性患者和394名献血者(均为抗-HCV阴性)。每位参与者通过OraSure和Salivette提供口腔液标本,并至少提供一个干血斑。尽可能从患者处采集血清标本。对于那些未提供血清标本的注射吸毒者,根据先前的检测确定其HCV状态。使用改良的Ortho HCV 3.0 SAVe酶联免疫吸附测定(ELISA)方案对所有非血清样本进行抗-HCV检测。改良ELISA推荐的初步临界值并不理想。此外,通过改变临界值并考虑所研究人群中HCV的可能流行率,可以提高敏感性、特异性以及阳性和阴性预测值。例如,对于抗-HCV流行率为50%的人群,改良检测方法在OraSure、Salivette和干血斑上的最佳敏感性分别为92%、83%和几乎100%,而使用初步临界值时分别为83%、59%和99%。各自的最佳特异性分别为99%、93%和100%。总之,通过OraSure装置采集的口腔液为在注射吸毒者中开展不仅针对HIV而且针对丙型肝炎的公共卫生监测提供了一种极其有用的方法。此外,干血斑标本可能对监测有用,并且可作为一线诊断标本。